197 related articles for article (PubMed ID: 21997416)
1. When activity requires breaking up: LEKTI proteolytic activation cascade for specific proteinase inhibition.
Furio L; Hovnanian A
J Invest Dermatol; 2011 Nov; 131(11):2169-73. PubMed ID: 21997416
[TBL] [Abstract][Full Text] [Related]
2. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.
Fortugno P; Bresciani A; Paolini C; Pazzagli C; El Hachem M; D'Alessio M; Zambruno G
J Invest Dermatol; 2011 Nov; 131(11):2223-32. PubMed ID: 21697885
[TBL] [Abstract][Full Text] [Related]
3. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.
Fortugno P; Furio L; Teson M; Berretti M; El Hachem M; Zambruno G; Hovnanian A; D'Alessio M
Hum Mol Genet; 2012 Oct; 21(19):4187-200. PubMed ID: 22730493
[TBL] [Abstract][Full Text] [Related]
4. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
5. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model.
Briot A; Lacroix M; Robin A; Steinhoff M; Deraison C; Hovnanian A
J Invest Dermatol; 2010 Dec; 130(12):2736-42. PubMed ID: 20703245
[TBL] [Abstract][Full Text] [Related]
6. rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients.
Roedl D; Oji V; Buters JT; Behrendt H; Braun-Falco M
J Dermatol Sci; 2011 Mar; 61(3):194-8. PubMed ID: 21251800
[TBL] [Abstract][Full Text] [Related]
7. A heterozygous null mutation combined with the G1258A polymorphism of SPINK5 causes impaired LEKTI function and abnormal expression of skin barrier proteins.
Di WL; Hennekam RC; Callard RE; Harper JI
Br J Dermatol; 2009 Aug; 161(2):404-12. PubMed ID: 19438860
[TBL] [Abstract][Full Text] [Related]
8. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients.
Komatsu N; Saijoh K; Jayakumar A; Clayman GL; Tohyama M; Suga Y; Mizuno Y; Tsukamoto K; Taniuchi K; Takehara K; Diamandis EP
J Invest Dermatol; 2008 May; 128(5):1148-59. PubMed ID: 17989726
[TBL] [Abstract][Full Text] [Related]
9. SPINK5, the defective gene in netherton syndrome, encodes multiple LEKTI isoforms derived from alternative pre-mRNA processing.
Tartaglia-Polcini A; Bonnart C; Micheloni A; Cianfarani F; Andrè A; Zambruno G; Hovnanian A; D'Alessio M
J Invest Dermatol; 2006 Feb; 126(2):315-24. PubMed ID: 16374478
[TBL] [Abstract][Full Text] [Related]
10. LEKTI-1 in sickness and in health.
Roelandt T; Thys B; Heughebaert C; De Vroede A; De Paepe K; Roseeuw D; Rombaut B; Hachem JP
Int J Cosmet Sci; 2009 Aug; 31(4):247-54. PubMed ID: 19467033
[TBL] [Abstract][Full Text] [Related]
11. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome.
Hachem JP; Wagberg F; Schmuth M; Crumrine D; Lissens W; Jayakumar A; Houben E; Mauro TM; Leonardsson G; Brattsand M; Egelrud T; Roseeuw D; Clayman GL; Feingold KR; Williams ML; Elias PM
J Invest Dermatol; 2006 Jul; 126(7):1609-21. PubMed ID: 16601670
[TBL] [Abstract][Full Text] [Related]
12. Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts.
Di WL; Larcher F; Semenova E; Talbot GE; Harper JI; Del Rio M; Thrasher AJ; Qasim W
Mol Ther; 2011 Feb; 19(2):408-16. PubMed ID: 20877344
[TBL] [Abstract][Full Text] [Related]
13. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.
Deraison C; Bonnart C; Lopez F; Besson C; Robinson R; Jayakumar A; Wagberg F; Brattsand M; Hachem JP; Leonardsson G; Hovnanian A
Mol Biol Cell; 2007 Sep; 18(9):3607-19. PubMed ID: 17596512
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of interleukin-33 in the epidermis of two Japanese patients with Netherton syndrome.
Konishi T; Tsuda T; Sakaguchi Y; Imai Y; Ito T; Hirota S; Yamanishi K
J Dermatol; 2014 Mar; 41(3):258-61. PubMed ID: 24506793
[TBL] [Abstract][Full Text] [Related]
15. Physiological and pathological roles of kallikrein-related peptidases in the epidermis.
Kishibe M
J Dermatol Sci; 2019 Aug; 95(2):50-55. PubMed ID: 31279501
[TBL] [Abstract][Full Text] [Related]
16. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.
Hovnanian A
Cell Tissue Res; 2013 Feb; 351(2):289-300. PubMed ID: 23344365
[TBL] [Abstract][Full Text] [Related]
17.
Park NJ; Jo BG; Bong SK; Park SA; Lee S; Kim YK; Yang MH; Kim SN
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955819
[TBL] [Abstract][Full Text] [Related]
18. Netherton syndrome in two Japanese siblings with a novel mutation in the SPINK5 gene: immunohistochemical studies of LEKTI and other epidermal molecules.
Shimomura Y; Sato N; Kariya N; Takatsuka S; Ito M
Br J Dermatol; 2005 Nov; 153(5):1026-30. PubMed ID: 16225619
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
Sugimoto S; Morizane S; Nomura H; Kobashi M; Sugihara S; Iwatsuki K
J Dermatol Sci; 2018 Nov; 92(2):181-187. PubMed ID: 30270115
[TBL] [Abstract][Full Text] [Related]
20. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.
Wiegmann H; Valentin F; Tarinski T; Liebau E; Loser K; Traupe H; Oji V
Br J Dermatol; 2019 Nov; 181(5):999-1008. PubMed ID: 30801672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
